TBPH · Theravance Biopharma, Inc.
Price & Indicators
Up next
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| YUPELRI net sales (Theravance Biopharma implied 35%) | $24.73M | the three months ended June 30, 2026 filing | — |
| Doses pulled through the hospital channel | 25% | Q2 2026 | — |
| Non-GAAP net income (loss) non-GAAP | 10.11M | Six Months Ended June 30 | — |
| Non-GAAP Net Income (Loss) from Operations non-GAAP | $9.5M | Q2 2026 | — |
| Operating expenses (excluding restructuring and transaction costs) | 35% | Q2 2026 | — |
| Q2 2026 TRELEGY net sales | $1B | Q2 2026 | — |
| Quarterly U.S. net sales of YUPELRI | $70.7M | Q2 2026 | — |
| YUPELRI net sales (100% recorded by Viatris) | 133.1M | Six Months Ended June 30 | — |
| Quarter-end cash balance | $395M | Q1 2026 | — |
| TRELEGY global net sales | $873M | Q1 2026 | — |
|
|
|||
| TRELEGY global net sales year-over-year growth | 2% | Q1 2026 | — |
| YUPELRI customer demand growth | 4% | Q1 2026 | — |
| YUPELRI Annual U.S. net sales | $266.6M | full year 2025 | — |
| YUPELRI net sales | $266.6M | FY 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TBPH
this stock
Theravance Biopharma, Inc.
|
$880.28M | -9.4% | -68.4% | 16.8 | 8.0% |
|
ONC
BeOne Medicines Ltd.
|
$557.05B | +21.5% | +22179.2% | 856.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$136.93B | +19.2% | +46.2% | 31.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$86.39B | +7.1% | +20.8% | 20.8 | 3.3% |
|
MRNA
Moderna, Inc.
|
$69.62B | +352.1% | +4.3% | — | 12.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TBPH | +0.2% | +0.5% | -7.1% | +0.5% | -9.4% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +2.1% | -2.8% | -18.3% | -1.6% | -21.2% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.